Nafamostat Mesylate Blocks Activation of SARS-CoV-2: New Treatment Option for COVID-19
Markus Hoffmann, Simon Schroeder, Hannah Kleine‐Weber, Marcel A. Müller, Christian Drosten, Stefan Pöhlmann
Abstract
Funder: \n Bundesministerium für Bildung und Forschung\n https://doi.org/10.13039/501100002347
Topics & Concepts
TMPRSS2CoronavirusVirologyMiddle East respiratory syndromeSerine proteaseBiologyBetacoronavirusPandemicMesylateProteaseProteasesCoronavirus disease 2019 (COVID-19)MedicineDiseaseChemistryInfectious disease (medical specialty)EnzymeInternal medicineBiochemistryOrganic chemistrySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesSARS-CoV-2 detection and testing